Concentrate on product kind, therapeutic class, pipeline, regional and nationwide information

Dublin, March 05, 2021 (GLOBE NEWSWIRE) – The “Global Cell and Gene Therapy Market: Focus on Product Type, Therapeutic Class, Pipeline, Regional and National Data (15 Countries) – Analysis and Forecast, 2021-2027” the report was added to from supply.

The worldwide cell and gene remedy market was valued at $ 2,599.7 million in 2020, and it’s anticipated to develop at a formidable double-digit fee of 33.82% and attain a price of $ 25,599.7 million in 2027 .

Cell remedy and gene remedy are overlapping areas of biomedical analysis and have related therapeutic targets, which goal DNA or RNA inside or outdoors the physique. Each therapies intention to change the genetic materials for the remedy of a illness. Gene remedy makes use of genetic materials, or DNA, to control a affected person’s cells for the remedy of an inherited or acquired illness.

Cell remedy includes introducing new cells right into a affected person’s physique to develop, substitute, or restore broken tissue to deal with illness. Cell and gene therapies are labeled into a number of therapeutic lessons, akin to uncommon ailments, oncology, hematology, heart problems, ophthalmology, neurology and others.

The present cell and gene remedy market is pushed by a number of components together with rising incidence of most cancers and different power ailments, rising variety of scientific trials, rising funding and investments within the cell and gene remedy market; and a positive regulatory setting and FDA approvals for cell and gene remedy merchandise.

Principal matters coated:

1 Product definition
1.1 Inclusion and exclusion

2 Analysis methodology
2.1 Major information sources
2.2 Secondary information sources
2.3 Market estimation mannequin
2.4 Choice standards for firm profiles

3 International Cell and Gene Remedy Market: International Perspective
3.1 Presentation
3.2 Cell and gene remedy and their scientific significance
3.3 Panorama of the event and commercialization of cell and gene remedy
3.4 International Cell and Gene Remedy Market Dimension, 2020-2027
3.5 Position of regulators and the consortium in cell and gene remedy
3.6 Reimbursement and market entry
3.6.1 Reimbursement Situation of Cell and Gene Remedy Market, by Nation United States Unit 5 France Germany Italy Spain United Kingdom
3.7 Key Cell and Gene Remedy Market Firms and Their Contributions

4 Market overview
4.1 Cell and Gene Remedy Business
4.2 Key Profitable Commercialization of Cell and Gene Remedy
4.2.1 Addressable regional market and development potential

5 Impression of the COVID-19 pandemic on the worldwide cell and gene remedy market
5.1 Cell and Gene Remedy Market Disruption Because of COVID-19
5.2 COVID-19 Affecting Cell and Gene Remedy Market Provide Chain
5.3 Interruption of scientific analysis and growth and industrial exploitation
5.3.1 Analysis and scientific growth
5.3.2 Industrial operation and entry
5.4 Navigate to restoration from a disaster and look to the long run

6 International Cell and Gene Remedy Market: Business Evaluation
6.1 Authorized and regulatory framework and necessities
6.1.1 Overview of regulatory pathway for cell and gene remedy Quick Observe designation: Revolutionary remedy: Accelerated approval: Precedence overview: Designation of superior remedy in regenerative drugs:
6.1.2 Expedited designation vs. Conventional approval instances:
6.1.3 Regulatory challenges
6.1.4 Profitable Regulatory Methods

7 Patent panorama

8 Manufacture of cell and gene remedy
8.1 Manufacture of viral vectors
8.1.1 Retrovirus
8.1.2 Lentivirus
8.1.3 AAV
8.1.4 Adenovirus
8.2 Upstream manufacturing
8.2.1 Consideration of prices and delays
8.2.2 Design of regulatory processes and burdens
8.2.3 Different concerns
8.3 Downstream manufacturing
8.3.1 Value and Time Concerns
8.3.2 Downstream challenges
8.3.3 Scaling up from analysis downstream to scientific manufacturing
8.4 Manufacture of non-viral vectors
8.4.1 Non-viral manufacture, with out plasmid
8.4.2 Plasmid
8.4.3 bare DNA
8.4.4 Bodily mediated strategies
8.5 Cell and Gene Remedy Manufacturing Capability, by Firm

9 International Cell and Gene Remedy Market: Market Dynamics
9.1 Overview
9.2 Market components
9.2.1 Rising Incidence of Most cancers and Different Persistent Illnesses
9.2.2 Excessive variety of uncommon ailments on the planet
9.2.3 Rising Variety of Medical Trials
9.2.4 Elevated Funding and Funding in Cell and Gene Remedy Market
9.2.5 Favorable regulatory setting for cell and gene remedy merchandise
9.3 Market restrictions
9.3.1 Lack of manufacturing of dependable vectors for cell and gene remedy
9.3.2 Complicated manufacturing and distribution setup
9.3.3 Tedious Therapeutic Advertising and marketing Course of
9.4 Market alternatives
9.4.1 Drug approvals and powerful cell and gene remedy portfolio
9.4.2 Rising variety of mergers and acquisitions inside the cell and gene business

10 International Cell and Gene Remedy Market: Aggressive Panorama
10.1 Key methods and growth
10.1.1 Product Affords and Approvals
10.2 Synergistic actions
10.3 Financing and enterprise enlargement
10.4 Mergers and acquisitions
10.5 Market Share Evaluation
10.6 Development Share Evaluation (by Firm), 2020

11 International Cell and Gene Remedy Market (By Product)
11.1 Therapeutic market
11.1.1 Yescarta
11.1.2 Provenge
11.1.3 Luxturna
11.1.4 Kymriah
11.1.5 Imlygic
11.1.6 Gintuit
11.1.7 MACI
11.1.8 Gendicin
11.1.9 Oncorin
11.1.10 Neovasculgen
11.1.11 Strimvelis
11.1.12 Invossa
11.1.13 Zolgensma
11.1.14 Tecartus
11.1.15 Liso-Cel
11.1.16 Zyntelego
11.1.17 Others
11.2 Evaluation of the pipeline
11.2.1 Section 1
11.2.2 Section 2
11.2.3 Section 3 SPK-8011 OTL-103 OTL-200 OTL-101 VM202 GS010 bb2121 PTC-AADC
11.2.4 Pipeline Evaluation – CAR-T Focus
11.2.5 Pipeline Evaluation – Targeted on CAR-NK

12 International Cell and Gene Remedy Market (By Therapeutic Class)
12.1 Overview
12.2 Uncommon ailments
12.3 Oncology
12.4 Hematology
12.5 Cardiovascular
12.6 Ophthalmology
12.7 Neurology
12.8 Different therapeutic lessons

13 International Cell and Gene Remedy Market (by Area)

14 firm profiles

  • Amgen Inc.
  • bluebird bio, Inc.
  • Dendreon Prescribed drugs LLC.
  • Citadel Creek Pharmaceutical Holdings
  • Institute of Human Stem Cells
  • Kite Pharma, Inc.
  • Kolon TissueGene, Inc.
  • Novartis AG
  • Orchard Therapeutics plc.
  • Organogenesis Holdings Inc.
  • Pfizer, Inc.
  • Shanghai Sunway Biotech Co., Ltd.
  • Sibiono GeneTech Co. Ltd.
  • Spark Therapeutics, Inc.
  • Vericel Company

For extra data on this report, go to

Laura Wooden, Senior Press Supervisor
[email protected]
For E.S.T Workplace Hours Name 1-917-300-0470
For U.S./CAN Toll Free Name 1-800-526-8630
For GMT Workplace Hours Name +353-1-416-8900

Source link

Comments are closed.